Literature DB >> 19379098

Comparison of the efficacy of a hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for eradication of Clostridium difficile spores.

F Barbut1, D Menuet, M Verachten, E Girou.   

Abstract

OBJECTIVE: To compare a hydrogen peroxide dry-mist system and a 0.5% hypochlorite solution with respect to their ability to disinfect Clostridium difficile-contaminated surfaces in vitro and in situ.
DESIGN: Prospective, randomized, before-after trial.
SETTING: Two French hospitals affected by C. difficile. INTERVENTION: In situ efficacy of disinfectants was assessed in rooms that had housed patients with C. difficile infection. A prospective study was performed at 2 hospitals that involved randomization of disinfection processes. When a patient with C. difficile infection was discharged, environmental contamination in the patient's room was evaluated before and after disinfection. Environmental surfaces were sampled for C. difficile by use of moistened swabs; swab samples were cultured on selective plates and in broth. Both disinfectants were tested in vitro with a spore-carrier test; in this test, 2 types of material, vinyl polychloride (representative of the room's floor) and laminate (representative of the room's furniture), were experimentally contaminated with spores from 3 C. difficile strains, including the epidemic clone ribotype 027-North American pulsed-field gel electrophoresis type 1.
RESULTS: There were 748 surface samples collected (360 from rooms treated with hydrogen peroxide and 388 from rooms treated with hypochlorite). Before disinfection, 46 (24%) of 194 samples obtained in the rooms randomized to hypochlorite treatment and 34 (19%) of 180 samples obtained in the rooms randomized to hydrogen peroxide treatment showed environmental contamination. After disinfection, 23 (12%) of 194 samples from hypochlorite-treated rooms and 4 (2%) of 180 samples from hydrogen peroxide treated rooms showed environmental contamination, a decrease in contamination of 50% after hypochlorite decontamination and 91% after hydrogen peroxide decontamination (P < .005). The in vitro activity of 0.5% hypochlorite was time dependent. The mean (+/-SD) reduction in initial log(10) bacterial count was 4.32 +/- 0.35 log(10) colony-forming units after 10 minutes of exposure to hypochlorite and 4.18 +/- 0.8 log(10) colony-forming units after 1 cycle of hydrogen peroxide decontamination.
CONCLUSION: In situ experiments indicate that the hydrogen peroxide dry-mist disinfection system is significantly more effective than 0.5% sodium hypochlorite solution at eradicating C. difficile spores and might represent a new alternative for disinfecting the rooms of patients with C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19379098     DOI: 10.1086/597232

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  40 in total

Review 1.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

Review 2.  Reducing Clostridium difficile in the Inpatient Setting: A Systematic Review of the Adherence to and Effectiveness of C. difficile Prevention Bundles.

Authors:  Anna K Barker; Caitlyn Ngam; Jackson S Musuuza; Valerie M Vaughn; Nasia Safdar
Journal:  Infect Control Hosp Epidemiol       Date:  2017-03-27       Impact factor: 3.254

Review 3.  Hospital Infection Control: Clostridioides difficile.

Authors:  Nicholas A Turner; Deverick J Anderson
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

4.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

5.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

6.  Effect of airborne hydrogen peroxide on spores of Clostridium difficile.

Authors:  Georg Steindl; Anita Fiedler; Steliana Huhulescu; Günther Wewalka; Franz Allerberger
Journal:  Wien Klin Wochenschr       Date:  2014-12-20       Impact factor: 1.704

7.  Evaluation of Peroxides and Chlorine Oxides as Disinfectants for Chemical Sterilization of Gnotobiotic Rodent Isolators.

Authors:  LaTisha V Moody; Yukiko Miyamoto; Jonathan Ang; Philip J Richter; Lars Eckmann
Journal:  J Am Assoc Lab Anim Sci       Date:  2019-07-18       Impact factor: 1.232

8.  Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens.

Authors:  Trevor D Lawley; Simon Clare; Laura J Deakin; David Goulding; Jennifer L Yen; Claire Raisen; Cordelia Brandt; Jon Lovell; Fiona Cooke; Taane G Clark; Gordon Dougan
Journal:  Appl Environ Microbiol       Date:  2010-08-27       Impact factor: 4.792

9.  Comparative antimicrobial activities of aerosolized sodium hypochlorite, chlorine dioxide, and electrochemically activated solutions evaluated using a novel standardized assay.

Authors:  R M S Thorn; G M Robinson; D M Reynolds
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  A simple decontamination approach using hydrogen peroxide vapour for Bacillus anthracis spore inactivation.

Authors:  J P Wood; M W Calfee; M Clayton; N Griffin-Gatchalian; A Touati; S Ryan; L Mickelsen; L Smith; V Rastogi
Journal:  J Appl Microbiol       Date:  2016-10-23       Impact factor: 3.772

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.